ArticleFrontiers in endocrinology2026
Metrnl as a predictive biomarker for postprandial hypertriglyceridemia in overweight and obese populations.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metrnl and macrophage polarization: role in skeletal muscle homeostasis and therapeutic potential.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The relationship between adipokine meteorin-like protein (Metrnl) and postprandial hypertriglyceridemia (PHTG) in overweight and obese populations remains unclear. This study examined the association between serum Metrnl and PHTG with normal fasting lipid profiles, using a standardized oral fat tolerance test (OFTT) to classify fat tolerance. The aim was to explore potential therapeutic targets for early obesity intervention. Patients and methods: We enrolled 105 adults with normal fasting lipid profiles who met Chinese lipid management criteria for low-risk atherosclerotic cardiovascular disease (ASCVD) prevention. Participants were grouped as control (CON), overweight (OW), or obese (OB). All underwent an OFTT, with venous blood collected fasting serum Metrnl, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), fasting insulin (FINS). Venous blood samples were collected at 1, 2, 3, and 4 hours postprandially to quantitatively analyze the dynamic changes in serum lipid profiles. Results: Serum Metrnl showed a significant negative correlation with PHTG (r = -0.473, P < 0.001), fasting TG (r = -0.370, P < 0.001), FINS (r = -0.261, P = 0.007). Multivariate regression identified fasting TG as a risk factor for PHTG. Each 0.1 mmol/L increment in fasting triglycerides was significantly associated with a 76.9% higher risk of PHTG. Metrnl was identified as protective (OR = 0.211, P < 0.001), the protective cutoff for Metrnl was 2.11ng/ml. A combined model of fasting TG and Metrnl improved PHTG prediction over fasting TG or Metrnl alone, with ROC analysis showing an AUC of 0.908, sensitivity of 82.7%, and specificity of 90.6%. Conclusions: Overweight and obese adults with normal fasting lipid profiles are at high risk of PHTG. Low serum Metrnl is closely associated with early lipid abnormalities and insulin resistance. Combining Metrnl with TG enhances diagnostic accuracy for PHTG.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.